# <sup>1</sup>**Health Utility Adjusted Survival: a Composite**

# <sup>2</sup>**Endpoint for Clinical Trial Designs**

- $\gamma$  Yangqing Deng<sup>1</sup>, PhD, John R. de Almeida<sup>2,3</sup>, MD, MSc, FRCSC, Wei Xu<sup>1,4\*</sup>, PhD
- <sup>1</sup> Department of Biostatistics, University Health Network, Toronto, ON, Canada
- <sup>2</sup> Department of Otolaryngology—H&N Surgery, University Health Network, Toronto, ON, Canada
- <sup>3</sup> Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
- <sup>4</sup> Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- 8 <sup>C</sup>orresponding author: Wei Xu, Email: wei.xu@uhnresearch.ca
- 9 Address: 10-511, 610 University Ave, Toronto, M5G 2M9
- 10 Tel: (416)946-4501

#### 11 ABSTRACT

12 Many randomized trials have used overall survival as the primary endpoint for establishing non-13 inferiority of one treatment compared to another. However, if a treatment is non-inferior to 14 another treatment in terms of overall survival, clinicians may be interested in further exploring 15 which treatment results in better health utility scores for patients. Examining health utility in a 16 secondary analysis is feasible, however, since health utility is not the primary endpoint, it is 17 usually not considered in the sample size calculation, hence the power to detect a difference of 18 health utility is not guaranteed. Furthermore, often the premise of non-inferiority trials is to test 19 the assumption that an intervention provides superior quality of life or toxicity profile without 20 compromising the survival when compared to the existing standard. Based on this consideration, 21 it may be beneficial to consider both survival and utility when designing a trial. There have been 22 methods that can combine survival and quality of life into a single measure, but they either have

1 strong restrictions or lack theoretical frameworks. In this manuscript, we propose a method 2 called HUS (Health Utility adjusted Survival), which can combine survival outcome and 3 longitudinal utility measures for treatment comparison. We propose an innovative statistical 4 framework as well as procedures to conduct power analysis and sample size calculation. By 5 comprehensive simulation studies involving summary statistics from the PET-NECK trial, $<sup>1</sup>$  we</sup> 6 demonstrate that our new approach can achieve superior power performance using relatively 7 small sample sizes, and our composite endpoint can be considered as an alternative to overall 8 survival in future clinical trial design and analysis where both survival and health utility are of 9 interest. 10

11 *Keywords*: Health utility; Overall survival; Time-to-event data; Hazard ratio; Proportional

12 hazards; Randomized controlled trials

# 1 1. INTRODUCTION

2 In many clinical studies, overall survival (OS) is used as the primary endpoint to assess efficacy 3 of treatments. Superiority trials are used to test whether a new treatment is better than a standard 4 or control treatment, while non-inferiority trials are used to test whether the new treatment is not 5 unacceptably worse than control. Non-inferiority trials are especially important in circumstances 6 where the new treatment may have other benefits (e.g., lower costs, fewer side effects, improved 7 quality of life, or is easier to implement) compared to control, and people are only interested in 8 showing the new treatment is not worse than control in terms of OS. When non-inferiority has 9 been established, clinicians may be interested in further examining whether the new treatment 10 can benefit patients more in terms of health utility.<sup>1</sup> Health utility is a construct, usually ranging 11 from 0 to 1 (although theoretically can also have negative values), that quantifies the preference 12 for a given health state experienced by a patient at a certain time point. A higher value means a 13 healthier state, while death usually corresponds to 0. Using health utility scores at different time 14 point during the treatment and post-treatment, statistical analysis may be performed to compare 15 different treatment groups' utility scores.  $2-4$  However, given that the study design is usually 16 based on the primary endpoint of OS without considering health utility, whether there will be 17 enough power for health utility analysis is uncertain. Also, conducting tests for OS and health 18 utility separately may not be the most efficient, because it involves multiple testing adjustment 19 and can lose statistical power. Hence, it may be beneficial to consider using a composite 20 endpoint that combines survival and utility, which may lead to increased statistical power and 21 smaller required sample sizes.

22

1 Creation of a composite endpoint of survival and utility, can also aid in clinical interpretation of 2 non-inferiority trials where non-inferiority of survival is not the only acceptable outcome. For 3 example, a new therapeutic intervention may be purported as offering improvements in quality of 4 life or toxicity. However, clinicians may not be willing to sacrifice disease control to provide 5 these other benefits. In this case, testing this new intervention in phase 3 non-inferiority trial 6 where overall survival is the primary outcome and quality of life or toxicity is a secondary 7 outcome may establish the intervention as non-inferior from a survival perspective and then 8 falsely identify the new intervention as a standard of care without appropriate consideration of 9 quality of life and toxicity. On the other hand, one may consider a situation where a patients' 10 preference for improved quality of life (or utility) may outweigh their desire to have non-inferior 11 survival. In this instance, demonstration of superiority of utility may not be enough if it is 12 associated with a significant loss of survival and the two outcomes cannot be interpreted in 13 isolation. In this instance, a combination of both survival and utility endpoints may be needed to 14 declare a new intervention superior.

15

16 Some methods that can combine survival and utility have been proposed and used to analyze 17 clinical trial data, and the most commonly used method is called Q-TWiST (Quality-adjusted 18 Time Without Symptoms of disease or Toxicity).<sup>5–12</sup> Though Q-TWiST has not been commonly 19 seen as a primary endpoint for designing new studies, researchers have derived its statistical 20 properties as well as formulas for sample size calculations.<sup>8</sup> That being said, one major issue 21 about Q-TWiST is that it divides each patient's status into three states (toxicity, time without 22 symptoms and toxicity, and relapse) and uses pre-selected weights for different states. In many 23 scenarios, with utility scores measured as continuous variables at different time points

1 throughout the trials, it may be much more desirable to analyze them in their original scales 2 rather than forcing to have three categories, which may likely result in loss of information and 3 decreased statistical power.

4

5 QALY (Quality-Adjusted Life Years), of which Q-TWiST can be considered as a special case, is 6 the most intuitive way to combine survival with utility when comparing different treatments.<sup>5, 13–</sup>  $17<sup>17</sup>$  It has also been used in the field of cost utility analysis, where similar methods have been 8 proposed and compared.<sup>18–21</sup> Quality-adjusted progression-free survival, a similar concept with 9 slightly different focus, has also been used to assess the benefits of different treatments in 10 randomized trials.<sup>22–24</sup> However, such measures have rarely been considered as a primary 11 endpoint for designing new trials, and we are not aware of any detailly developed statistical 12 framework or comprehensive simulation studies that demonstrate the advantages and feasibility 13 of a quality-adjusted survival endpoint compared to the traditional survival endpoint. 14

15 With these limitations and considerations, we propose an innovative composite endpoint for 16 combining longitudinal health utility and survival, called HUS (Health Utility adjusted Survival), 17 with a detailed statistical testing framework as well as procedures to perform power analysis and 18 sample size calculations. By assigning weights to health utility and survival, HUS can be 19 modified to suit different scenarios with increased power.

20

21 This new endpoint may help better interpret the findings in clinical trials. Often non-inferiority 22 trials are plagued with uncertainty of the efficacy of a new intervention that is statistically 23 deemed non-inferior based mainly on survival estimates but that has not been clearly shown to

1 be more effective from a toxicity reduction or quality of life improvement perspective. In Table 1, 2 we provide several scenarios of how the new composite endpoint of HUS may improve 3 interpretation of clinical trial findings if this composite endpoint was used in place of standard 4 primary endpoints. For example, one may consider three scenarios in which a new treatment is 5 deemed non-inferior based on a primary outcome of survival in a typical non-inferiority design 6 where different utility scores may produce drastically different trial conclusions if a composite 7 HUS endpoint were used. If a new intervention had lower utility than the comparator, a non-8 inferior trial would declare the new intervention non-inferior, when in fact, a HUS endpoint 9 would appropriately declare the new intervention inferior. In addition, as we will show in the 10 simulations, sufficient power may be achieved with smaller sample sizes to make statistical 11 inferences than non-inferiority trials based on a non-inferiority margin of survival. This feature 12 may improve the efficiency of trial conduct and arriving at meaningful conclusions with smaller 13 samples.

14

15 This manuscript is structured as follows. In section 2, we present the methodology of the HUS 16 endpoint, including its construction, sample size calculation and power analysis. In section 3, we 17 use comprehensive simulation studies with various settings, including scenarios incorporating 18 parameter estimates based on the PET-NECK trial<sup>1</sup> to demonstrate the power advantage of HUS 19 when analyzing study data and its potential to reduce required sample sizes when designing new 20 trials. At last, we provide a discussion on the advantages, limitations and future directions for 21 HUS in section 4.

22

# 1 2. METHODS

### 2 2.1. HEALTH UTILITY ADJUSTED SURVIVAL (HUS)

3 In this section, we describe the basic framework of Health Utility adjusted Survival (HUS). In

4 many clinical studies, overall survival is chosen as the primary endpoint, which determines the

5 sample size, while health utility scores are usually analyzed in the secondary analyses. To

6 construct a composite endpoint combining survival and health utility, we can take the product of

7 the survival curve and the utility curve, as illustrated by Figure 1.

8

9 Suppose the total length of the study follow up time is  $T$ , and we are interested in comparing  $\Omega$  survivel and beelth utility between treatment groups 1 and 2. We define a  $\Omega$  statistic to represe

10 survival and health utility between treatment groups 1 and 2. We define a Q statistic to represent

11 the HUS of each treatment group as

$$
Q_1 = \int_0^T S_1(t)\overline{U}_1(t)dt,
$$
  
\n
$$
Q_2 = \int_0^T S_2(t)\overline{U}_2(t)dt,
$$
\n(2)

12 where  $S_1(t)$  and  $U_1(t)$  are the survival function (proportion of patients alive at t) and average 13 utility score of those alive at t for group 1.  $S_2(t)$  and  $U_2(t)$  are the survival function and average 14 utility score of those alive at  $t$  for group 2. We propose to use the Kaplan Meier (KM) estimated  $\theta$ 15 survival functions  $\ddot{S}_1(t)$ ,  $\ddot{S}_2(t)$  to substitute  $S_1(t)$ ,  $S_2(t)$ .

16

17 We can also assign weights to the survival and utility separately by defining

$$
Q_1 = \int_0^T [S_1(t)]^{\lambda_1} [\overline{U}_1(t)]^{\lambda_2} dt,
$$
  
\n
$$
Q_2 = \int_0^T [S_2(t)]^{\lambda_1} [\overline{U}_2(t)]^{\lambda_2} dt.
$$
\n(4)

If  $\lambda_1 = 0$  and  $\lambda_2 = 1$ , then  $Q_1$  and  $Q_2$  only consider the utility functions without including 2 survival. If  $\lambda_1 = 1$  and  $\lambda_2 = 0$ , then  $Q_1$  and  $Q_2$  simply calculate the areas under the survival 3 curves without adjusting for utility. For simplicity, we suggest fixing the weight  $\lambda_1$  as 1, since 4 survival is usually considered as important.  $\lambda_2$  can be chosen from different values (e.g., 0.5, 1, 2), and  $\lambda_2 = 1$  leads to the standard definition of HUS. The higher  $\lambda_2$  is, the more importance is 6 assigned to health utility. For the rest of this manuscript, we focus on  $\lambda_1 = 1$  and  $\lambda_2 = 1$  unless 7 otherwise specified. We will also show some results with various  $\lambda_2$  in our simulation studies 8 and discuss its effect.

 $\overline{a}$ 

9

#### 10 2.2. HYPOTHESIS TESTING

11 To examine the difference of HUS between two treatment groups, we can define the test statistic 12 as

$$
\mathcal{T} = Q_1 - Q_2. \tag{5}
$$

13 To perform a one-sided test on whether group 1 has better HUS than group 2, we can either use 14 the bootstrap method to obtain the confidence interval of  $T$ , or use the permutation method to to 15 obtain the distribution of  $T$  under the null hypothesis.<sup>25</sup> We can reject or accept the null 15 16 hypothesis (H0:  $T \le 0$ ) based on bootstrap confidence intervals. Suppose groups 1 and 2 have  $n_1$ 

and  $n_2$  subjects respectively, and the chosen significance threshold is  $\alpha$ . The bootstrap procedure 2 can be described as follows:

3 1. For iteration  $b$  ( $b = 1, ..., B$ ), take a bootstrap dataset from the original samples, meaning 4 that we randomly sample  $n_1$  subjects with replacement from treatment group 1 to be group 1 in the new sample,  $n_2$  subjects with replacement from treatment group 2 to be group 2 in the step 2 in the 6 new sample. 2. Calculate the  $T$  test statistic for the new sample, denoted by  $T^{(b)}$ . 3. After obtaining  $T^{(b)}$ 's ( $b = 1, ..., B$ ), calculate the  $(1 - \alpha)$  confidence interval based on 9 these  $B$  bootstrap samples. If the confidence interval does not contain 0, reject the null  $\theta$ 10 hypothesis. Note that the confidence interval should be constructed based on the test of 11 interest (one-sided or two-sided). 12 The permutation procedure can be described as follows: 13 1. For iteration  $b$  ( $b = 1, ..., B$ ), permute on the original samples to get a new permutation 14 dataset, meaning that we randomly reassign all of the subjects into two groups with sample 15 sizes  $n_1$  and  $n_2$ . 2. Calculate the  $T$  test statistic for the new sample, denoted by  $T^{(b)}$ . 3. After obtaining  $T^{(b)}$ 's ( $b = 1, ..., B$ ), calculate the  $(1 - \alpha)$  confidence interval based on 18 these *B* permutation samples. If the observed test statistic  $T$  is outside the confidence interval, 19 reject the null hypothesis. 20 Note that the distribution generated by bootstrap is under the alternative hypothesis, whereas the

21 distribution generated by permutation is under the null hypothesis, which is why the former is

22 compared with 0, while the latter is compared with the observed test statistic. Based on our

1 experience, both bootstrap and permutation methods can control type I errors, but bootstrap tends 2 to have slightly higher power than permutation. Hence, we focus on the bootstrap method by 3 default. Some simulation results comparing bootstrap and permutation can be found in the 4 supplementary materials (Table S4, Figure S1). Besides, as hinted by Glasziou et al.,<sup>13</sup> Jackknife resampling can also be used to obtain the distribution of  $T$  under the alternative hypothesis.<sup>26, 27</sup> 5.5  $^{25}$ 6 However, our past experience shows that there is little difference in terms of type I error and 7 power when comparing the bootstrap method with Jackknife, while the distribution of  $T$  based  $T$ 8 on bootstrap samples tends to be closer to normal. As a result, we suggest using the bootstrap 9 method as default. In terms of the number of resamples,  $B = 500$  is usually sufficient for 10 controlling type I errors and obtaining decent power. Examples showing the performance of 11 Jackknife and evaluating the choice of  $B$  are also provided in the supplementary materials 12 (Tables S4-S5, Figure S1).

13

#### 14 2.3. THEORETICAL PROPERTIES

15 If we assume the survival time follows a piecewise exponential distribution, we can derive a 16 Monte Carlo approach to calculate the variance of the test statistic, which can be used for power 17 analysis and sample size calculation.<sup>28</sup> A similar idea was used by Royston and Parmar<sup>29</sup> to 18 calculate the variance for restricted mean survival time (RMST).  $30-32$ 

19

20 We consider a simple case with three key time points: 0 (baseline),  $C$  (end of surgery) and  $T$  (end  $T$ )

21 of study). Focusing on one treatment group, suppose the survival time is piecewise exponential,

22 with piecewise constant hazards  $h_1, h_2$  for time periods 0~C, C~T respectively. The utility

23 function is piecewise linear, which starts from  $A_1$  at time 0, changes to  $A_2$  at time C, and then

- 1 goes to  $A_3$  at time T. Let  $X = min(\xi, T)$ , where  $\xi$  is the survival time with cumulative hazard
- function  $H(t)$  and survival function  $S(t)$ . We can decompose X as  $X_1 + X_2$ , where

$$
X_1 = \begin{cases} \xi & (0 \le \xi \le C) \\ C & (\xi > C) \end{cases} \tag{6}
$$

$$
X_2 = \begin{cases} 0 & (0 \le \xi \le C) \\ \xi - C & (C < \xi \le T) \\ T - C & (\xi > T) \end{cases} \tag{7}
$$

- Denote  $M = \int_{t=0}^{1} S(t) U_0(t) dt$ 3 Denote  $M = \int_{t=0}^{T} S(t)U_0(t)dt$  where  $U_0(t)$  is the base utility function for the currently
- considered treatment group. Write its statistic of HUS as  $Q = \int_{t=0}^{\infty} \dot{S}(t) U(t) dt$ 4 considered treatment group. Write its statistic of HUS as  $Q = \int_{t=0}^{1} \dot{S}(t)U(t)dt$ . If we define

$$
X^* = A_1 X_1 + \frac{T A_2 - C A_3}{T - C} X_2 + \frac{A_2 - A_1}{2C} X_1^2 + \frac{A_3 - A_2}{2(T - C)} X_2^2 + \frac{A_3 - A_2}{T - C} X_1 X_2, \tag{8}
$$

5 we can derive that  $M = E(X^*)$ . Following Royston & Parmar (2013), we can assume that for a 6 specific scenario, we have

$$
SE(Q) = \phi \frac{SD(X^*)}{\sqrt{n}},
$$
\n(9)

7 where  $\phi$  is a factor no less than 1 and *n* is the sample size for the group we are currently looking 8 at. For convenience, we call  $\phi$  the variance balance factor, which takes account of the extra variance introduced into HUS by missing utility, censored survival, KM estimation, etc.  $SD(X^*)$ 10 can be calculated using the parameters, while  $\phi$  can be estimated by Monte Carlo sampling. 11 More details including the derivations are provided in the supplementary materials (Tables S2- 12 S3). We will demonstrate in our simulations that  $\phi$  is robust to different sample sizes.

1 Note that when two treatment groups are compared, they should have their own variance balance 2 factors, which we denote as  $\phi_1$  and  $\phi_2$ . Applying our assumed property to each of the groups, 3 we have

$$
SE(Q_1) = \phi_1 \frac{SD(X^*_{1})}{\sqrt{n_1}},
$$
\n(10)

$$
SE(Q_2) = \phi_2 \frac{SD(X^*_{2})}{\sqrt{n_2}},
$$
\n(11)

4 where  $Q_1$  and  $Q_2$  are the statistics of HUS for treatment groups 1 and 2, and  $n_1$ ,  $n_2$  are the

5 sample sizes of the two groups.  $X^*$ <sub>1</sub> and  $X^*$ <sub>2</sub> are constructed separately for the two groups using

their own parameter settings. Hence, the variance of 6 their own parameter settings. Hence, the variance of  $T = Q_1 - Q_2$  is

$$
var(\mathcal{T}) = [SE(Q_1)]^2 + [SE(Q_2)]^2.
$$
 (12)

7 For the one-sided test, we can reject the null hypothesis if  $T - z_{1-\alpha}\sqrt{\text{var}(T)} > 0$ .

8

### 9 2.4. POWER ANALYSIS AND SAMPLE SIZE CALCULATION

10 In any scenario with prespecified parameters, given different sample size, we can calculate the 11 corresponding power of HUS using simulations. Then we can obtain a table showing different 12 power under different sample sizes, which can be used to determine the sample size needed to 13 achieve specific power (e.g., 80%) for a new trial. Detailed examples are provided in section 3.1. 14

15 If we assume that the special case described in section 2.3 is true, then we only need to run one

16 simulation given a fixed sample size (e.g., 200 subjects per treatment group), which can give us

1 estimates of  $\phi_1$  and  $\phi_2$ . For the one-sided test where we reject the null hypothesis if  $T -$ 

2  $z_{1-\alpha}\sqrt{\text{var}(\mathcal{T})} > 0$ , the power is

$$
\omega = P\left(\mathcal{T} - z_{1-\alpha}\sqrt{\text{var}(\mathcal{T})} > 0\right) = P\left(\mathcal{T} > z_{1-\alpha}\sqrt{\text{var}(\mathcal{T})}\right).
$$
\n(13)

Assume  $T$  follows  $N(T_{true}, \text{var}(T))$  and denote the power by  $\omega$ , we have

$$
\omega = \Phi \left( \frac{\mathcal{T}_{\text{true}}}{\sqrt{\text{var}(\mathcal{T})}} - z_{1-\alpha} \right),\tag{14}
$$

- 4 where Φ is the cumulative distribution function of the standard normal distribution. On the other
- 5 hand, to achieve power  $\omega$ , the required sample sizes should satisfy

$$
\phi_1^2 \frac{\text{SD}(X^*)^2}{n_1} + \phi_2^2 \frac{\text{SD}(X^*)^2}{n_2} = \left(\frac{\mathcal{T}_{\text{true}}}{\Phi^{-1}(\omega) + z_{1-\alpha}}\right)^2.
$$
\n(15)

6 If we assume  $n_1 = n_2$ , then the required sample size per arm is

$$
n_1 = \frac{(\Phi^{-1}(\omega) + z_{1-\alpha})^2 [\phi_1^2 \text{var}(X_{1}^*) + \phi_2^2 \text{var}(X_{2}^*)]}{T_{\text{true}}^2}.
$$
 (16)

7 Note that it is difficult to calculate  $T_{true}$  based on the setting of parameters. However, we can 8 estimate it by using the average of the observed  $T$  from our simulated samples. To summarize, in 9 the special situation with simplified settings described in section 2.3, we can use the following 10 procedure to calculate power yielded by a specific sample size:

- 11 1. Calculate  $var(X^*_{1})$ ,  $var(X^*_{2})$  based on parameter settings.
- 12 2. Simulate samples to estimate  $\phi_1$ ,  $\phi_2$  and  $T_{true}$ .
- 13 3. For each new sample size combination  $n_1$ ,  $n_2$ , calculate  $SE(Q_1)$ ,  $SE(Q_2)$  using the estimated

$$
14 \qquad \phi_1, \phi_2.
$$

1 4. Calculate var  $(\mathcal{T})$  and power  $\omega$ .

2

3 On the other side, we can use the following procedure to calculate the sample size required to 4 achieve specific power:

5 1. Calculate  $var(X^*_{1})$ ,  $var(X^*_{2})$  based on parameter settings.

6 2. Simulate samples to estimate  $\phi_1$ ,  $\phi_2$  and  $T_{true}$ .

3. Calculate  $n_1$  using the sample size formula.

8

### 9 2.5. HANDLING MISSING UTILITY SCORES

10 In clinical studies, utility scores may not be available at each time point for all subjects, while the 11 current framework of HUS requires complete utility profiles to calculate the test statistic. The 12 most intuitive way is to impute the utility scores. We use linear functions to fill in the utility 13 scores using the available data. If a subject's utility score is only available at one time point, then 14 we use that score as the imputed utility at all other time points. This approach may seem simple, 15 but it can be quite effective. Another method we consider is to impute the group average at each 16 key time point (i.e., each time point at which at least one subject has their utility score recorded), 17 and then use linear functions to fill in the other missing scores. This approach can be regarded as 18 a combination of the cross-mean and linear interpolation methods<sup>33</sup>. While imputing the group 19 average, we can also add some variation using a normal distribution with mean zero and its 20 standard deviation equal to the standard deviation of the recorded scores at that time point. In 21 this way, the imputed values may be closer to the true values, which may lead to increase of 22 statistical power. It is also worth noting that many other methods are available for imputing 23 longitudinal data, and a very recent study has compared the effects of different imputation

1 methods and shown that most of them are similar in various scenarios, whereas trajectory mean 2 single imputation has the best overall performance<sup>33</sup>. Hence, we consider trajectory mean 3 imputation as a third method. A comparison of the three methods using simulation results is 4 provided in the supplementary materials (Table S1), which shows that method 1 has much worse 5 performance when the missing rate is higher, while methods 2 and 3 are not affected as much. 6 For convenience, we use method 2 by default.

# 7 3. RESULTS

## 8 3.1. SIMULATIONS WITH SIMPLIFIED SETTINGS

#### 9 *3.1.1 POWER COMPARISON*

10 We conduct simulations in various scenarios to assess the performances of HUS. Suppose we are 11 designing a randomized clinical trial with two treatment arms. The total length of study is 36 12 months ( $T = 36$ ), and each patient receives surgery at 3 months ( $C = 3$ ). The two arms are 13 assigned to different treatment strategies to help them recover, and we are interested in 14 comparing the two treatments in terms of both survival and health utility. Denote the true survival time, observed survival time and survival status for patient *i* from group *g* as  $T_{gi}$ ,  $X_{gi}$ ,  $X_{gi}$ 16 and  $\delta_{qi}$  respectively. Group 1 and group 2 have sample sizes  $n_1$  and  $n_2$ . The survival data is 17 simulated using

$$
T_{gi} \sim \text{Exp}(h_g),
$$

$$
\xi_{gi} \sim \text{Unif}(0, \zeta),
$$

$$
X_{gi} = \min(T_{gi}, \xi_{gi}, T),
$$

$$
\delta_{gi} = \begin{cases} 1 & (T_{gi} < \xi_{gi} \text{ and } T_{gi} < T) \\ 0 & (otherwise) \end{cases}
$$

where  $\zeta$  is chosen to control the censoring rate, denoted by  $p_{\text{censoring}}$ . The hazard ratio of

```
2 treatment 1 against treatment 2 is h_1/h_2.
```
3

4 To simulate the health utility score, we first define base utility functions for the two groups. The

5 base utility at time  $t$  for group  $g$  can be written as

$$
U_{g0}(t) = \begin{cases} A_{g1} + \frac{A_{g2} - A_{g1}}{C}t & (0 \le t \le C) \\ \frac{TA_{g2} - CA_{g3}}{T - C} + \frac{A_{g3} - A_{g2}}{T - C}t & (C < t \le T) \end{cases}
$$

6 This definition means the average utility for group g starts from  $A_{g1}$  at baseline, changes to  $A_{g2}$ 7 at 3 months, and then changes to  $A_{g3}$  at the end of the study. The change is piecewise linear. Our 8 motivation for this setting is that usually a cancer patient's health utility reaches the lowest at the 9 end of treatment and gradually recovers after that. For patient  $i$  from group  $g$ , the health utility score at time t, denoted by  $U_{gi}(t)$ , follows a normal distribution with mean  $U_{g0}(t)$  and standard is 11 deviation 0.1.

12

13 In practice, we do not expect health utility scores to be collected at each time point. Furthermore, 14 some of the scores scheduled to be collected may be missing. For our main simulation study, we 15 assume that the health utility scores are only collected at  $t = 1$ ,  $C$  and  $T$ . When  $t = 1$ , all 16 subjects have their utility scores collected. When  $t = C$  or T, the subjects that are still being 17 followed have their utility scores collected, while there is a  $p_{\text{missingU}}$  chance that the score is 18 missing.

1 In this section, we focus on the situation where the two treatment groups do not have a difference 2 in OS, which is the situation that motivated our HUS framework. Other situations (e.g., the two 3 treatment groups differ in both OS and health utility) are explored in section 3.2 and the 4 supplementary materials (Tables S6-S9). Table 2 shows a summary of our major scenarios. In 5 each scenario, we compare the theoretical rejection rate using our results from section 2.4 and 6 the empirical rejection rates of HUS using bootstrap with  $B = 500$ . We consider three choices of  $\lambda_2$ :  $\lambda_2 = 1$  corresponds to the standard HUS approach;  $\lambda_2 = 0.5$  means giving utility less weight 8 than survival;  $\lambda_2 = 2$  means giving utility more weight than survival. We also examine the 9 performance of OS-based tests. In the tables, "sup" represents the log-rank test that tests whether 10 group 1 is superior to group 2 in terms of OS using KM estimates. "5%" and "10%" correspond 11 to the inferiority test using the hazard ratio with margins 5% and 10% respectively. For instance, 12 a 5% margin means we establish non-inferiority (treatment 1 is non-inferior to treatment 2 in 13 terms of OS) if the upper bound of the 95% CI of the hazard ratio is smaller than 1.05.

14

15 In scenario 0, we examine the rejection rates of different methods when the two treatment groups 16 have the same OS and health utility. As shown in Table 3, all of the superiority tests are able to 17 control type I errors at 0.05. The rejection rates of the non-inferiority tests are power instead of 18 type I errors, since the alternative is true (treatment 1 is not inferior to treatment 2). This is why 19 they may be higher than 0.05.

20

21 In scenario 1, we compare the power of different methods when treatment group 1 has better 22 health utility than treatment group 2. For the theoretical power analysis, firstly, we run one 23 simulation with  $n_1 = n_2 = 200$  and 4000 replications to obtain the estimates  $\phi_1 = 1.07$ ,  $\phi_2 =$ 

1 1.12,  $T_{true}$  = 3.11. Then we can calculate the power of different sample sizes. For the other 2 methods such as bootstrap  $\lambda_2 = 1$ ,  $\lambda_2 = 0.5$ , and  $\lambda_2 = 2$ , we need to simulate new datasets (200 is replications) with different sample sizes to get the empirical power. Note that  $\phi_1$ ,  $\phi_2$  and  $T_{true}$ 4 are quite robust to different sample sizes. For example, if we use  $n_1 = n_2 = 500$ , the obtained 5 estimates are  $\phi_1 = 1.06$ ,  $\phi_2 = 1.11$ ,  $T_{true} = 3.11$ , which is very close to the scenario of  $n_1 =$ 6  $n_2 = 200$ . More results regarding the variance balance factors are provided in the supplementary 7 materials (Tables S2-S3).

8

9 As shown in Table 4, the bootstrap method with  $\lambda_2 = 1$  performs close to the theoretical results, 10 which makes sense since the theoretical results are based on the standard HUS with  $\lambda_2 = 1$ . 11 Larger  $\lambda_2$  tends to lead to higher power by giving more weight to utility than survival. This is 12 also expected because the two groups only differ in terms of utility. Meanwhile, the superiority 13 and non-inferiority tests based on OS have little power since there is no real difference in the two 14 group's OS. We also calculate the power corresponding to different sample sizes using our 15 theoretical results and plot the power curves in Figure 2. For scenario 1, to achieve 80% power, 16 using HUS as the endpoint only requires 85 subjects per arm.

17

18 In scenario 2, we increase the censoring rate to 60% and missing rates to 60%, and reduce the 19 difference between the two group's health utility scores. As shown in Table 4 and Figure 2, 20 results are very similar to those in scenario 1. Again, HUS is able to obtain decent power with 21 relatively small sample sizes while the superiority and non-inferiority tests struggle to find 22 enough evidence to show treatment 1's benefit compared to treatment 2. If we design a trial

1 based on HUS with the assumptions in scenario 2, we only need to have 151 patients in each 2 treatment group.

3

4 We would like to point out that even though choosing a larger  $\lambda_2$  may seem to have higher 5 power in the above scenarios, it may not always be a good choice, especially when there is a 6 difference in OS. We recommend using  $\lambda_2 = 1$  as default, though it can be modified depending 7 on the knowledge of the two treatments (e.g., whether treatment 1 is likely to have better OS than 8 treatment 2).

9

#### 10 *3.1.2 SAMPLE SIZE CALCULATION*

11 In this subsection, we use our developed sample size calculation formulas to calculate sample 12 sizes needed for the composite endpoint, and the standard formulas to calculate sample sizes 13 needed for basic survival endpoint (implemented in PASS 2023, v23.0.2 with the one-sided log-14 rank test), to further demonstrate the advantage of HUS. Following scenario 1 from 3.1.1, where 15 treatment 1 has better utility than treatment 2, we consider four different cases. In the first case, 16 there is no survival difference, which is consistent with the focus of this manuscript, and the 17 endpoint overall survival does not have power. In the second case, we assume that treatment 1 18 has better survival than treatment 2, while in the third case, we assume that treatment 2 has better 19 survival. In the last case, we assume treatment 1 has better survival, but there is no difference in 20 utility, and the utility function is the same as that in scenario 0. As shown in Table 5, with 21 scenario 1's utility functions, when  $h_1$  is smaller than  $h_2$ , meaning that treatment 1 has better OS 22 than treatment 2, the required sample size for HUS is decreased, which makes sense because the 23 difference in HUS is larger. When  $h_1$  is larger than  $h_2$ , meaning that treatment 1 has worse OS

1 than treatment 2, the required sample size for HUS is increased. Nevertheless, the numbers are 2 still much smaller than those calculated for overall survival. If there is no utility difference, HUS 3 will require more subjects than overall survival, which is expected, though the difference is not 4 as big. These results show again that using the composite endpoint may help greatly reduce the 5 required sample size to detect a significant difference when two treatments differ in utility. 6

7 **Table 5.** Sample size calculation under a significance level of 0.05. When there is a utility

- 8 difference, utility functions from scenario 1 are used. When there is no utility difference, utility
- 9 functions from scenario 0 are used.





1

2

### 3 3.3. SIMULATIONS WITH REAL DATA ESTIMATES

4 To demonstrate the benefit of HUS in a more practical scenario, we conduct additional 5 simulations with average utility scores and the hazard ratio mimicking the summary data 6 provided in a real randomized trial PET-NECK.<sup>1</sup> PET-NECK is a randomized phase III non-7 inferiority trial that compares Positron emission tomography-computerized tomography-guided 8 watch-and-wait policy (PET-CT) with planned neck dissection (planned ND) for head and neck 9 cancer patients. The two-year overall survival rates of the two treatment groups (PET-CT and 10 planned ND) with 282 subjects per arm, are 84.9% and 81.5% respectively, which leads to a 11 hazard ratio of 0.80. We conducted simulations utilizing the parameter setting to emulate the 12 survival times in PET-NECK. Figure 3 shows the average utility scores at different time points in 13 the study, with the maximum time being 24 months. Hence, in this scenario, we set  $T = 24$  and 14 define the base utility functions following the observed average utility scores. We also record the 15 utilities at baseline and months 1, 3, 6, 12, 24 with 30% missing rate. Note that this scenario does 16 not fall into the framework of section 2.3, and thus we cannot apply our theoretical results 17 directly to calculate the power and sample sizes. However, obtaining the empirical results is 18 similar to what we describe in section 3.1.

1



# 12 4. DISCUSSION

13 We have presented a methodological framework to compare two treatment groups using HUS as 14 a composite endpoint combining survival and health utility. As demonstrated by our 15 comprehensive simulation studies, when there is a difference in health utility, HUS has a 16 significant power advantage over the statistical tests based on OS endpoint, meaning that using 17 HUS as an endpoint for new trials may require much smaller sample sizes to achieve decent 18 power. We have also demonstrated two different procedures (theoretical and empirical 19 approaches) to conduct power analysis and sample size calculation with specified parameters. 20 When the model assumptions are met, the two procedures yield similar results. 21 There are several different options when applying HUS. We recommend using bootstrap given 22 its popularity as well as its convenience of constructing confidence intervals for the test statistic,

1 though permutation may be theoretically more appropriate for testing the null hypothesis, since it 2 can obtain the null distribution of the test statistic. In terms of weighting on survival and utility, we recommend choosing weights  $\lambda_1 = \lambda_2 = 1$  as default. Using a larger  $\lambda_2$  may increase the 4 power in certain scenarios, especially when the two treatment groups differ in health utility but 5 not in OS. However, it may not be beneficial when there is no difference in health utility. A 6 possible way to combine different weighting options without having to choose one is to apply an 7 idea similar to the aSPU test.<sup>34, 35</sup>

8

9 Note that the theoretical properties we have presented are based on assumptions by analogy with 10 the assumptions used by Royston and Parmar,<sup>29</sup> though we have shown the validity of our 11 theoretical results in our simulations. In the future, we may explore the asymptotic properties 12 with relaxed assumptions (e.g., the survival times do not have to be piece-wise exponential), 13 which would be helpful when designing or analyzing trials where our previously used 14 assumptions are likely to be violated. We would also like to point out that the linear imputation 15 method we use to fill in the utility scores may be problematic in some cases, especially if the 16 scores are only recorded at a few time points and the missing rate is high. We may consider other 17 imputation methods or modifying the definition of HUS so that it does not require complete 18 utility score profiles as input.<sup>36, 37</sup> Besides that, given the possible drawbacks brought by KM 19 estimates, sometimes it may be beneficial to apply other models, including the flexible 20 parametric model for survival analysis. $38$ 

21

22 Another possible direction worth exploring is to take different functions of the utility score into 23 consideration. One special case is that in many clinical studies, multiple measures of health

1 status are recorded. There are various ways to combine different measures into a single utility  $\frac{39-41}{7}$  Extending HUS to be able to handle any function of utility may potentially increase 3 power and help us gain insight on how the utility is different in different treatment groups. 4 Furthermore, considering utility may have different importance at different time points, we may 5 assign different weights across time. For example, having a better utility score at the later stage 6 of the study, which means the patients have recovered better, may be more important than having 7 a better utility score at the end of surgery. In such case, we can consider giving higher weights to 8 later time points, and the resulted HUS may provide a clearer picture of which treatment is more 9 beneficial for recovery.

10

## 11 5. DATA AVAILABILITY

12 R code for our simulation studies and summary data of health utility are available at

13 https://github.com/yangq001/HUS.

14

### 15 CONFLICTS OF INTEREST

16 The authors declare that there are no conflicts of interest.

17

## 18 ACKNOWLEDGMENTS

- 19 The authors would like to acknowledge the contributions of Dr. Hisham Mehanna (Institute of
- 20 Head and Neck Studies and Education, University of Birmingham) and Dr. Sue Yom
- 21 (Department of Radiation Oncology, University of California) for clinical insights and discussion.

1

# 2 FUNDING

- 3 This work was supported by the Alan Brown Chair in Molecular Genomics, the Lusi Wong Family Fund,
- 4 and the Posluns Family Fund, all through the Princess Margaret Cancer Foundation.

5

# **REFERENCES**

**1**. Mehanna H, McConkey CC, Rahman JK, et al: PET-NECK: a multicentre randomised Phase III noninferiority trial comparing a positron emission tomography–computerised tomography-guided watch-andwait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess 21:1–122, 2017

**2**. Mathias SD, Bates MM, Pasta DJ, et al: Use of the Health Utilities Index With Stroke Patients and Their Caregivers. Stroke 28:1888–1894, 1997

**3**. Horsman J, Furlong W, Feeny D, et al: The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health Qual Life Outcomes 1:54, 2003

**4**. Jewell EL, Smrtka M, Broadwater G, et al: Utility Scores and Treatment Preferences for Clinical Early-Stage Cervical Cancer. Value in Health 14:582–586, 2011

**5**. Glasziou PP, Simes RJ, Gelber RD: Quality adjusted survival analysis. Statist Med 9:1259–1276, 1990

**6**. Gelber RD: Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer. Ann Intern Med 114:621, 1991

**7**. Gelber RD, Goldhirsch A, Cole BF, et al: A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Adjuvant Radiation Therapy and Chemotherapy for Resectable Rectal Cancer. JNCI Journal of the National Cancer Institute 88:1039–1045, 1996

**8**. Murray S, Cole B: Variance and Sample Size Calculations in Quality-of-Life-Adjusted Survival Analysis (Q-TWiST). Biometrics 56:173–182, 2000

**9**. Konski AA, Winter K, Cole BF, et al: Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: Phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. Head Neck 31:207–212, 2009

**10**. Zbrozek AS, Hudes G, Levy D, et al: Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma. Pharmacoeconomics 28:577–584, 2010

**11**. Seymour JF, Gaitonde P, Emeribe U, et al: A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients. Blood 138:3722–3722, 2021

**12**. Jerusalem G, Delea TE, Martin M, et al: Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial. Clinical Breast Cancer 22:326–335, 2022

**13**. Glasziou PP, Cole BF, Gelber RD, et al: Quality adjusted survival analysis with repeated quality of life measures. Stat Med 17:1215–1229, 1998

**14**. Prieto L, Sacristán JA: Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes 1:80, 2003

**15**. Whitehead SJ, Ali S: Health outcomes in economic evaluation: the QALY and utilities. British Medical Bulletin 96:5–21, 2010

**16**. Touray MML: Estimation of Quality-adjusted Life Years alongside clinical trials: the impact of 'timeeffects' on trial results. J Pharm Health Serv Res 9:109–114, 2018

**17**. Chung C-H, Hu T-H, Wang J-D, et al: Estimation of Quality-Adjusted Life Expectancy of Patients With Oral Cancer: Integration of Lifetime Survival With Repeated Quality-of-Life Measurements. Value in Health Regional Issues 21:59–65, 2020

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.04.08.24305511;](https://doi.org/10.1101/2024.04.08.24305511) this version posted April 9, 2024. The copyright holder for this preprint

**18**. Laska EM, Meisner M, Siegel C: Power and Sample Size in Cost- Effectiveness Analysis. Med Decis Making 19:339–343, 1999

**19**. Willan AR, Lin DY: Incremental net benefit in randomized clinical trials. Statist Med 20:1563–1574, 2001

**20**. Hollingworth W, McKell-Redwood D, Hampson L, et al: Cost–utility analysis conducted alongside randomized controlled trials: Are economic end points considered in sample size calculations and does it matter? Clinical Trials 10:43–53, 2013

**21**. Bader C, Cossin S, Maillard A, et al: A new approach for sample size calculation in cost-effectiveness studies based on value of information. BMC Med Res Methodol 18:113, 2018

**22**. Billingham LJ, Abrams KR, Jones DR: Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess 3:1–152, 1999

**23**. Diaby V, Adunlin G, Ali AA, et al: Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat 146:669–673, 2014

**24**. Oza AM, Lorusso D, Aghajanian C, et al: Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. JCO 38:3494–3505, 2020

**25**. Good PI: Permutation, parametric and bootstrap tests of hypotheses 3rd ed. New York, Springer, 2005

**26**. Wu CFJ: Jackknife, Bootstrap and Other Resampling Methods in Regression Analysis [Internet]. Ann Statist 14, 1986[cited 2022 Dec 14] Available from: https://projecteuclid.org/journals/annals-ofstatistics/volume-14/issue-4/Jackknife-Bootstrap-and-Other-Resampling-Methods-in-Regression-Analysis/10.1214/aos/1176350142.full

**27**. Shao J, Tu D: The Jackknife and Bootstrap [Internet]. New York, NY, Springer New York, 1995[cited 2022 Dec 14] Available from: http://link.springer.com/10.1007/978-1-4612-0795-5

**28**. Myers ND, Ahn S, Jin Y: Sample Size and Power Estimates for a Confirmatory Factor Analytic Model in Exercise and Sport: A Monte Carlo Approach. Research Quarterly for Exercise and Sport 82:412–423, 2011

**29**. Royston P, Parmar MKB: Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 13:152, 2013

**30**. Irwin JO: The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice. J Hyg 47:188–189, 1949

**31**. Royston P, Parmar MKB: The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statist Med 30:2409– 2421, 2011

**32**. Zhao L, Claggett B, Tian L, et al: On the restricted mean survival time curve in survival analysis: On the Restricted Mean Survival Time Curve in Survival Analysis. Biom 72:215–221, 2016

**33**. Jahangiri M, Kazemnejad A, Goldfeld KS, et al: A wide range of missing imputation approaches in longitudinal data: a simulation study and real data analysis. BMC Med Res Methodol 23:161, 2023

**34**. Pan W, Kim J, Zhang Y, et al: A Powerful and Adaptive Association Test for Rare Variants. Genetics 197:1081–1095, 2014

**35**. Kim J, Bai Y, Pan W: An Adaptive Association Test for Multiple Phenotypes with GWAS Summary Statistics. Genet Epidemiol 39:651–663, 2015

**36**. Naeim A, Keeler EB, Mangione CM: Options for Handling Missing Data in the Health Utilities Index Mark 3. Med Decis Making 25:186–198, 2005

**37**. Graham JW: Missing Data [Internet]. New York, NY, Springer New York, 2012[cited 2022 Dec 14] Available from: http://link.springer.com/10.1007/978-1-4614-4018-5

**38**. Lambert PC, Royston P: Further Development of Flexible Parametric Models for Survival Analysis. The Stata Journal 9:265–290, 2009

**39**. Hawthorne G, Richardson J, Day NA: A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Annals of Medicine 33:358–370, 2001

**40**. Fisk JD: A comparison of health utility measures for the evaluation of multiple sclerosis treatments. Journal of Neurology, Neurosurgery & Psychiatry 76:58–63, 2005

**41**. Pickard AS, Ray S, Ganguli A, et al: Comparison of FACT- and EQ-5D–Based Utility Scores in Cancer. Value in Health 15:305–311, 2012



**Table 1.** Interpretations for different scenarios of survival and utility.



# **Table 2.** Simulation settings with different scenario.



**Table 3.** Rejection rates of different methods in scenario 0 based on 1000 replications.



**Table 4.** Power comparison of different methods in scenarios 1 and 2 based on 200 replications.





**Table 6.** Power comparison for simulations using real data estimates.









